Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age21+
SponsorNatalie Lockney
About this trial
This is a study to establish a safe and feasible dose for prophylactic use of a combination of gabapentin and ketamine in head and neck cancer patients undergoing chemoradiation.
Eligibility criteria
Qualifiers
Histologically proven cancer of the head and neck cancer
Locally advanced non-metastatic disease (T3N0M0, T4N0M0, T1-4N1-3M0)
Planned primary or adjuvant radiation or chemoradiation therapy
Willing and able to provide informed consent
Disqualifiers
Currently on gabapentin or ketamine
Prior non-tolerance of gabapentin or ketamine
Unable to administer ketamine intranasally due to anatomical restrictions
History of seizure disorder
Trial design
Treatments tested in this trial
- Gabapentin
- Ketamine
Treatment groups
64 Participants
are divided into 1 treatment groupLocations
1Vanderbilt-Ingram Cancer Center37232, NashvilleTennessee, United States
Sponsors and collaborators
Natalie Lockney
Lead sponsor
Vanderbilt-Ingram Cancer Center
Sponsor institution
Source ClinicalTrials.gov